Tango Therapeutics, Inc.
tangotx.comWhat Do They Do?
Develops targeted small-molecule cancer drug candidates for patient groups identified by specific genetic changes, including people with pancreatic, lung and brain cancers.
10-K for FY2025, filed Mar 5, 2026
How Do They Make Money?
Tango earns collaboration revenue mainly through agreements with Gilead: a partner pays for licensed drug programs, with upfront license fees tied to the partner being able to use the license, and for research services as Tango performs them.
10-K for FY2025, filed Mar 5, 2026The Company’s revenues were primarily generated through its license and collaboration agreements with Gilead. Refer to Note 3…View ↗
Exclusive License Rights — If the license to the Company’s intellectual property is determined to be distinct from the other promises or…View ↗
Research and Development Services — The obligations under the Company’s collaboration agreements may include research and development…View ↗
$62.4M
-
10-K for FY2025, filed Mar 5, 2026
$62.4M ↗
Who Are Their Customers?
Pharmaceutical collaborators work with Tango under licensing and research agreements; Gilead has been the main source of collaboration revenue.
10-K for FY2025, filed Mar 5, 2026
Do Revenues Turn Into Profits?
No. It lost $101.6M in FY2025.
10-K for FY2025, filed Mar 5, 2026
−$111.3MView ↗
10-K for FY2025, filed Mar 5, 2026
−$101.6MView ↗
10-K for FY2025, filed Mar 5, 2026
−$139.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$55.3MView ↗
- ▲ +42% (Loss)
- vs −$38.9M in Q2 FY2025
-
Aug 11, 2026
Robert Azelby becomes board chair
Sources
8-K, filed Aug 11, 2026
Board of Directors. In June, the Company strengthened its Board of Directors with the appointment of Robert Azelby, adding more than 30…View ↗
-
Aug 6, 2026
Executive Chair Barbara Weber leaves the company and board
Her employment ended, and she resigned from all officer and board positions.
Sources
8-K, filed Aug 6, 2026
Dr. Barbara Weber’s employment with Tango Therapeutics, Inc. (the “Company”) as its Executive Chair ended on August 3, 2026 in accordance…View ↗
-
Jun 8, 2026
Combination trial results support planned pancreatic cancer Phase 3
Tango reported a 92% objective response rate in pancreatic cancer and intends to advance the combination to Phase 3.
Sources
8-K, filed Jun 8, 2026
In the vopimetostat plus daraxonrasib dose escalation arm, patients received either vopimetostat 200 mg or 250 mg once daily (“QD”) plus…View ↗
-
May 8, 2026
CFO Daniella Beckman leaves
Sources
8-K, filed May 8, 2026
As previously announced, on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined…View ↗
Growing. Revenue grew 68% in 4 years, from $37M in FY2021 to $62.4M in FY2025, about 14% a year.
Who Do They Compete With?
Competes with AstraZeneca, Amgen, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck KGaA, Pfizer, Lilly, Roche, Artios Pharma, BeOne, Exelixis, IDEAYA Biosciences, Repare Therapeutics, Servier Pharmaceuticals, Abbisko, Insilico Medicine, and Jubilant Therapeutics
10-K for FY2025, filed Mar 5, 2026We face direct competition from pharmaceutical and biotechnology companies leveraging the principle of synthetic lethality as well as…View ↗
Loading...
